医学
成纤维细胞生长因子受体
尿路上皮癌
肿瘤科
尿路上皮癌
临床试验
人口
转移性尿路上皮癌
内科学
重症监护医学
癌症
膀胱癌
成纤维细胞生长因子
受体
环境卫生
作者
Andrea Franza,Marta Pirovano,Patrizia Giannatempo,Laura Cosmai
出处
期刊:Future Oncology
[Future Medicine]
日期:2022-06-01
卷期号:18 (19): 2455-2464
被引量:1
标识
DOI:10.2217/fon-2021-1151
摘要
FGFR inhibitors represent a new and promising therapeutic approach to urothelial cancer (UC). Erdafitinib (Balversa©) was the first FGFR inhibitor approved for the treatment of metastatic UC, showing proper pharmacological activity and a consistent safety profile in a population with limited or no therapeutic alternatives. While results from comparative phase II and III trials are needed to assess the efficacy of erdafitinib in different clinical settings, there are still questions unsolved regarding a typical class effect of FGFR inhibitors, hyperphosporemia. In this review, the authors focus on the state-of-art administration of erdatifinib in advanced UC, pointing out the more recent evidence, pitfalls and possible future research. Insight on the management of hyperphosporemia in patients undergoing treatment with FGFR inhibitors is also provided.
科研通智能强力驱动
Strongly Powered by AbleSci AI